Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral...
Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024
June 13, 2023 08:00 ET
|
Candel Therapeutics
Based on forthcoming completion of patient enrollment and duration of follow-up in Cohort 2 from the phase 2 trial in late-stage NSCLC NEEDHAM, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- Candel...
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
June 08, 2023 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral...
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
June 05, 2023 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral...
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
May 19, 2023 09:00 ET
|
Candel Therapeutics
Treatment with CAN-3110 in arm A showed encouraging median overall survival rate at 11.8 months after a single injection. These data are supported by independent cohort (arm B); median overall...
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
May 11, 2023 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and...
Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
May 02, 2023 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies...
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
April 17, 2023 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and...
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
March 30, 2023 08:00 ET
|
Candel Therapeutics
Expects to announce clinical trial data from multiple oncology programs in the second half of 2023Extends cash runway into second quarter of 2024 NEEDHAM, Mass., March 30, 2023 (GLOBE...
Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day
February 01, 2023 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that...